Registered title, quoted from ClinicalTrials.gov
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07126678, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically confirmed diagnosis of grade I, II, or IIIa follicular lymphoma (FL), treatment-naïve, stage III-IV disease, and meeting treatment criteria (GELF criteria);
Inclusion criterion 5
All patients of childbearing potential must agree to use effective contraception during the study and for 24 months after treatment cessation; women of childbearing potential must have a negative urine pregnancy test before treatment initiation.
Inclusion criterion 11
Received lymphoma-directed therapy within 2 weeks prior to enrollment;
Exclusion criterion 2
Liver function: AST (SGOT), ALT (SGPT) ≤2.5×ULN (without liver involvement) or ≤5×ULN (with liver involvement); total bilirubin (TBIL) ≤ULN; serum creatinine (CRE) ≤1.5×ULN;
Inclusion criterion 8
Creatinine clearance ≥30 mL/min (calculated by Cockcroft-Gault formula);
Inclusion criterion 9
Known active hepatitis C virus (HCV) infection; other acquired/congenital immunodeficiency disorders, including HIV infection;
Exclusion criterion 14
Malignancies treated with curative intent and no evidence of disease for ≥5 years before enrollment;
Exclusion criterion 17
Pregnant or breastfeeding women;
Exclusion criterion 21
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07126678, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntary participation with signed informed consent;
- Age ≥18 years and ≤75 years, regardless of gender;
- Life expectancy ≥3 months;
- ECOG performance status 0-2; patients with ECOG 3 may be enrolled only if their decline in performance status is disease-related and the investigator judges they may benefit from treatment;
- Histologically confirmed diagnosis of grade I, II, or IIIa follicular lymphoma (FL), treatment-naïve, stage III-IV disease, and meeting treatment criteria (GELF criteria);
- Measurable and/or evaluable lymphoma lesions;
- Adequate bone marrow reserve: absolute neutrophil count (ANC) >1.0×10⁹/L or platelets >75×10⁹/L, unless cytopenia is deemed related to bone marrow infiltration by lymphoma and the investigator believes it may recover;
- Liver function: AST (SGOT), ALT (SGPT) ≤2.5×ULN (without liver involvement) or ≤5×ULN (with liver involvement); total bilirubin (TBIL) ≤ULN; serum creatinine (CRE) ≤1.5×ULN;
- Creatinine clearance ≥30 mL/min (calculated by Cockcroft-Gault formula);
- Ability to comply with study visit schedules and other protocol requirements;
- All patients of childbearing potential must agree to use effective contraception during the study and for 24 months after treatment cessation; women of childbearing potential must have a negative urine pregnancy test before treatment initiation.
Exclusion Criteria:
- Grade IIIb FL or transformed FL;
- Received lymphoma-directed therapy within 2 weeks prior to enrollment;
- Any severe medical condition, including but not limited to:
- Poorly controlled hypertension (defined as failure to achieve control despite lifestyle modifications and treatment with at least 3 maximally tolerated antihypertensive drugs [including diuretics] for ≥4 weeks, or requiring ≥4 antihypertensive drugs for adequate control);
- Uncontrolled congestive heart failure (NYHA class 3 [moderate] or 4 [severe]) within 6 months prior to screening;
- Left ventricular ejection fraction (LVEF) <50%;
- Symptomatic coronary artery disease (e.g., chest pain, palpitations, fatigue) or requiring medication;
- Severe bradycardia (heart rate <40 bpm), hypotension, dizziness, or syncope; patients with arrhythmia history require cardiac evaluation;
- Active bacterial, viral, fungal, or other infections (except for nail fungal infections) or major infections within 2 weeks before the first dose of study drug;
- Moderate to severe liver disease (Child-Pugh B or C);
- Active bleeding within 2 months before screening or clinically significant bleeding tendency per investigator judgment;
- Pulmonary conditions impairing function (e.g., pulmonary fibrosis, drug-induced pneumonitis) deemed intolerable by the investigator;
- Any psychiatric or cognitive impairment that may compromise understanding of informed consent, protocol compliance, or study adherence;
- Known active hepatitis C virus (HCV) infection; other acquired/congenital immunodeficiency disorders, including HIV infection;
- Central nervous system (CNS) involvement by lymphoma;
- Diagnosis or treatment for malignancies other than lymphoma, except:
- Malignancies treated with curative intent and no evidence of disease for ≥5 years before enrollment;
- Adequately treated basal cell carcinoma (excluding melanoma) with no evidence of disease;
- Adequately treated cervical carcinoma in situ with no evidence of disease;
- Hypersensitivity to any study drug;
- Pregnant or breastfeeding women;
- History of stroke or intracranial hemorrhage within 6 months before enrollment;
- Requiring anticoagulation with warfarin or equivalent vitamin K antagonists;
- Requiring chronic use of strong CYP3A inhibitors;
- Administration of live attenuated vaccines within 4 weeks before study entry.
Quoted from ClinicalTrials.gov, NCT07126678, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07126678, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.